Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute–Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005

1 Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

2 Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

3 Department of Rheumatology, Felix-Platter Spital, Basel, Switzerland

4 Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin, Milwaukee, Wisconsin

5 Department of Neurology, University of Washington, Seattle, Washington

6 Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland

7 Departments of Hematology and Internal Medicine, University of Basel, Kantonsspital, Basel, Switzerland

8 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

9 Division of Rheumatology, Department of Medicine, University of Texas-Houston Health Science Center, Houston, Texas

10 Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland

11 Blood and Marrow Transplant Program, Presbyterian/St. Luke’s Medical Center, Rocky Mountain Cancer Center, Denver, Colorado

12 Department of Neurology, City of Hope National Medical Center, Duarte, California

13 Bone Marrow Transplant Unit, UO Ematologia, Policlinico Careggi, Florence, Italy

14 Clinical Research Division, Fred Hutchinson Cancer Research Center, and University of Washington, Seattle, Washington

15 Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California